Human pharmacology of the opioid neuropeptide dynorphin A(1-13)

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1154-1163

  Greenwald, Mark K ^a,b   Stitzer, Maxine L ^a   Haberny, Kathleen A ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN[1-13]; MANNITOL; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NALOXONE; NEUROPEPTIDE; NORBINALTORPHIMINE; OPIATE PEPTIDE; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HEART RATE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORPHINE ADDICTION; OPIATE ADDICTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; SKIN TEMPERATURE; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYNORPHINS; HUMANS; MALE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0030921475     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. ACETO, M. D. AND BOWMAN, E. R.: Blockade of dynorphin A(1-13) overt psychomotor effects by naloxone. Peptides 13: 847-849, 1992.
2. ACETO, M. D., DEWEY, W. L., CHANG, J. K. AND LEE, N. M.: Dynorphin-(1-13): Effects in nontolerant and morphine-dependent rhesus monkeys. Eur. J. Pharmacol. 83: 139-142, 1982.
3. AZORLOSA, J., STITZER. M. L. AND GREENWALD, M. K.: Opioid physical dependence development: Effects of single versus repeated morphine pretreatments and of subjects' opioid exposure history. Psychopharmacology 114: 71-80, 1994.
4. BALLA. J., GOLI, V., URBAN, B., HARRIS, T., GAYAM, R. AND KRISHNAN, R.: The effects of dynorphin on pain in chronic pain patients treated with methadone. American Pain Society, 12th Annual Scientific Meeting Abstract 93543, 1993.
5. BICKEL, W. K., STITZER, M. L., LIEBSON, I. A. AND BIGELOW, G. E.: Acute physical dependence in man: Effects of naloxone after brief morphine exposure. J. Pharmacol. Exp. Ther. 244: 126-132, 1988.
6. BRASE, D. A., IWAMOTO, E. T., LOH, H. H. AND WAY, E. L.: Reinitiation of sensitivity to naloxone by a single narcotic injection in postaddicted mice. J. Pharmacol. Exp. Ther. 197: 317-325, 1976.
7. BUTELMAN, E. R., FRANCE, C. P, AND WOODS, J. H.: Agonist and antagonist effects of dynorphin A(1-13) in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 275: 374-380, 1995.
8. CHAVKIN, C. AND GOLDSTEIN, A.: Specific receptor for the opioid peptide dynorphin: Structure-activity relationships. Proc. Natl. Acad. Sci. U.S.A. 78: 6543-6547, 1981.
9. CHAVKIN, C., JAMES, I. F. AND GOLDSTEIN, A.: Dynorphin is a specific endogenous ligand of the κ receptor. Science 215: 413-415, 1982.
10. CHOU, J. Z., KREEK, M. J. AND CHAIT, B. T.: Matrix-assisted laser desorption mass-spectroscopy of biotransformation products of dynorphin A. J. Am. Soc. Mass. Spectrom. 5: 10-16, 1994.
11. CORBETT, A. D., PATERSON, S. J., MCKKNIGHT, A. T., MAGNAN, J. AND KOSTERLITZ, H. W.: Dynorphin-(1-8) and dynorphin-(1-9) are ligands for the κ-subtype of opiate receptor. Nature 299: 79-81, 1982.
12. EISSENBERG, T., GREENWALD, M. K., JOHNSON, R. E., LIEBSON, I. A., BIGELOW, G. E. AND STITZER, M. L.: Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. J. Pharmacol. Exp. Ther. 276: 449-459, 1996.
13. EMMERSON, P. J., LIU, M. R., WOODS, J. H. AND MEDZIHRADSKY, F.: Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271: 1630-1637, 1994.
14. FRIEDMAN. H. J., JEN, M. F., CHANG, J. K., LEE, N. M. AND LOH, H. H.: Dynorplun: A possible modulatory peptide on morphine or β-endorphin analgesia in mouse. Eur. J. Pharmacol. 69: 351-360, 1981.
15. GOLDSTEIN, A., TACHIBANA, S., LOWNEY, L. I., HUNKAPILLER, M. AND HOOD, L.: Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. U.S.A. 76: 6666-6670, 1979.
16. GREEN. P-G. AND LEE, N. M.: Dynorphin A-(1-13) attenuates withdrawal in morphine-dependent rats: Effect of route of administration. Eur. J. Pharmacol 145: 267-272, 1988.
17. GREENWALD, M. K., JUNE, H. L., STITZER, M. L. , AND MARCO, A. P.: Comparative clinical pharmacology of short-acting mu opioids in drug abusers. J. Pharmacol. Exp. Ther. 277: 1228-1236, 1996.
18. HAYES, A. G., SKINGLE, M. AND TYERS, M. B.: Antinociceptive profile of dynorphin in rats. Life Sci. 33: 657-660, 1983.
19. HEISHMAN, S. J., STITZER, M. L., BIGELOW, G. E. AND LIEBSON I. A.: Acute opioid physical dependence in postaddict humans: Naloxone dose effects after brief morphine exposure. J. Pharmacol. Exp. Ther. 248: 127-134, 1989a.
20. HEISHMAN, S. J., STITZER, M. L., BIGELOW, G. E. AND LIEBSON, I. A.: Acute opioid physical dependence in humans: Effect of varying the morphine-naloxone interval I. J. Pharmacol. Exp. Ther. 250: 485-491, 1989b.
21. HEISHMAN, S. J., STITZER, M. L., BIGELOW, G. E. AND LIEBSON, I. A.: Acute opioid physical dependence in humans: Effect of naloxone at 6 and 24 hours postmorphine. Pharmacol. Biochem. Behav. 36: 393-399, 1990.
22. HERMAN, B. H.: Intrathecal dynorphin induces antinociception and paralysis. Soc. Neurosci. Abstr. 8: 91, 1982.
23. HERMAN, B. H. AND GOLDSTEIN, A.: Antinociception and paralysis induced by intrathecal dynorphin A. J. Pharmacol. Exp. Ther. 232: 27-32, 1985.
24. 2-dynorphin-(1-11) in rats. Life Sci. 27: 883-892, 1980.
25. HIMMELSBACH, C. K.: The morphine abstinence syndrome: Its nature and treatment. Ann. Intern. Med. 15: 829-839, 1941.
26. 1]Dynorphin A-(12-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther. 273: 802-807, 1995.
27. HUIDOBRO-TORO, J. P., YOSHIMURA, K., LEE, N. M., LOH, H. H. AND WAY, E. L.: Dynorphin interaction at the κ-opiate site. Eur. J. Pharmacol. 72: 265-266, 1981.
28. JAFFE, J. H. AND MARTIN, W. R.: Opioid analgesics and antagonists. In The Pharmacological Basis of Therapeutics, ed. by A. G. Gilman, T. W. Rall, A. S. Niles and P. Taylor, 8th ed., pp. 485-521, Pergamon Press, New York, 1990.
29. KANEKO, T., NAKAZAWA, T., IKEDA, M., YAMATSU, K., IWAMA, T., WADA, T., SATOH, M AND TAKAGI, H.: Sites of analgesic action of dynorphin. Life Sci. 33: suppl. 1, 661-664, 1983.
30. KHACHATURIAN, H., WATSON, S. J., LEWIS, M. E., COY, D., GOLDSTEIN, A. AND AKIL, H.: Dynorphin immunocytochemistry in the rat central nervous system. Peptides 3: 941-954, 1982.
31. 2-dynorphin-(1-11) (kappa agonists) in morphine (mu opioid agonist)-dependent rats. Life Sci. 33: suppl. 1, 559-562, 1983.
32. KIRBY, K. C., STITZER, M. L. AND HEISHMAN, S. J.: Acute opioid physical dependence in humans: Effect of varying the morphine-naloxone interval II. J. Pharmacol. Exp. Ther. 255: 730-737, 1990.
33. KUMOR, K., JOHNSON, R. E., JASINSKI, D. R. AND KOCHER, T.: Comparative profile of the pharmacological activities of ketocyclazocine (K), morphine (M), cyclazocine (C), and placebo (P) in man (Abstract). Pharmacologist 26: 162, 1984.
34. KUMOR, K., SU, T.-P., VAUPEL, B., HAERTZEN, C., JOHNSON, R. E. AND GOLDBERG, S.: Studies of kappa agonist. In Problems of Drug Dependence 1985, ed. by S. Harris. Proceedings of the 47th Annual Scientific Meeting, College on Problems of Drug Dependence, NIDA Monograph 67, pp. 18-25, 1986.
35. LESLIE, F. M, AND GOLDSTEIN, A.: Degradation of dynorphin-( 1-13) by membrane-bound rat brain enzymes. Neuropeptides 2: 185-196, 1982.
36. LONG, J. B., PETRAS, J. M., MOBLEY, W. C. AND HOLADAY, J. W.: Neurological dysfunction after intrathecal injection of dynorphin A(1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function. J. Pharmacol. Exp. Ther. 246: 1167-1174, 1988.
37. MASSAUDIER, D. AND HUNT, P. F.: A direct nonopiate interaction of dynorphin(1-13) with N-methyl-d-aspartate (NMDA) receptor. Eur. J. Pharmacol. 170: 125-126, 1989.
38. MAYSINGER, D., HOLLT, V., SEIZINGER, P., MEHRAEIN, P., PASI, A. AND HERZ, A.: Parallel distribution of immunoreactive α-neo-endorphin and dynorphin in rat and human tissue. Neuropeptides 2: 211-225, 1982.
39. NAKAZAWA, T., IKEDA, M., KANEKO, T. AND YAMATSU, K.: Analgesic effects of dynorphin-A and morphine in mice. Peptides 6: 75-78, 1985.
40. OKA, T., NEGISHI, K., SUDA, M., SAWA, A., FUJINO, M. AND WAKIMASU, M.: Evidence that dynorphin-(1-13) acts as an agonist on opioid κ-receptors. Eur. J. Pharmacol. 77: 137-141, 1982.
41. PFEIFFER, A., BRANTL, V., HERZ, A. AND EMRICH, H.: Psychotomimesis mediated by κ opiate receptors. Science 233: 774-776, 1986.
42. PFEIFFER, A., PASI, A., MEHRAEIN, P. AND HERZ, A.: A subclassification of κ-sites in human brain by use of dynorphin 1-17. Neuropeptides 2: 89-97, 1981.
43. PICKWORTH, W. B., NEIDERT, G. L. AND KAY, D. C.: Cyclazocine-induced sleep disruptions in nondependent addicts. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 10: 77-85, 1986.
44. PIERCEY, M. F., VARNER, K. AND SCHROEDER, L. A.: Analgesic activity of intraspinally administered dynorphin and ethylketocyclazocine. Eur. J. Pharmacol. 80: 283-284, 1982.
45. PRESTON, K. L. AND BIGELOW, G. E.: Subjective and discriminative effects of drugs. Behav. Pharmacol. 2: 293-313, 1991.
46. PRESTON, K. L., BIGELOW, G. E., BICKEL, W. K. AND LIEBSON, I. A.: Drug discrimination in human postaddicts: Agonist-antagonist opioids. J. Pharmacol. Exp. Ther. 250: 184-196, 1989.
47. PRZEWLOCKI, R., SHEARMAN, G. T. AND HEHZ, A.: Mixed opioid/nonopioid effects of dynorphin and dynorphin-related peptides after their intrathecal injection in rats. Neuropeptides 3: 233-240, 1983.
48. SCHMAUSS, C. AND HERZ, A.: Intrathecally administered dynorphin-(1-17) modulates morphine-induced antinociception differently in morphine-naive and morphine-tolerant rats. Eur. J. Pharmacol. 135: 429-431, 1987.
49. SMITH, A. P. AND LEE, N. M.: Pharmacology of dynorphin. Annu. Rev. Pharmacol. Toxicol. 28: 123-140, 1988.
50. SOFUOGLU, M., SATO, J. AND TAKEMORI, A. E.: Maintenance of morphine dependence by naloxone in acutely dependent mice. J. Pharmacol. Exp. Ther. 254: 841-846, 1990.
51. SONG, Z. H. AND TAKEMORI:, A. E.: Modulation of acute morphine tolerance by corticotropin-releasing factor and dynorphin A in the mouse spinal cord. Life Sci. 51: 107-111, 1992.
52. SPAMPINATO, S. AND CANDELETTI, S.: Characterization of dynorphin-A induced antinociception at the spinal level. Eur. J. Pharmacol. 110: 21-30, 1985.
53. SPECKER, S., WANANUKUL, W., NOLIN, K., HATSUKAMI, D. AND PENTEL, P.: Effects of dynorphin on opiate addiction in humans. 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR, 1996.
54. STEVENS, C. W. AND YAKSH, T. L.: Dynorphin A and related peptides administered intrathecally in the rat: A search for putative kappa opiate receptor activity. J. Pharmacol. Exp. Ther. 238: 833-838, 1986.
55. SULLIVAN, J. T., JOHNSON, R. E., TESTA, M. P., STITZER, M. L. AND JASINSKI, D. R.: Development of a method to screen for opiate withdrawal suppressing drugs: Clonidine effects (Abstract). Clin. Pharmacol. Ther. 55: 131, 1994.
56. TAKEMORI, A. E., LOH, H. H. AND LEE, N, M.: Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221: 223-226, 1992.
57. 1] dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266: 121-124, 1993.
58. TULUNAY, F. C., JEN, M. F., CHANG, J. K., LOH, H. H. AND LEE, N. M.: Possible regulatory role of dynorphin on morphine and β-endorphin-induced analgesia. J. Pharmacol. Exp. Ther. 219: 296-298, 1981.
59. TUNG, A. S. AND YAKSH, T. L.: In vivo evidence for multiple opiate receptors mediating analgesia in the rat spinal cord. Brain Res. 247: 75-83, 1982.
60. TYERS, M. B.: A classification of opiate receptors that mediate antinociception in animals. Br. J. Pharmacol. 69: 503-512, 1980.
61. UPTON, N., SEWELL, R. D. E. AND SPENCER, P. S. J.: Differentiation of potent μ-and κ-opiate agonists using heat and pressure antinociceptive profiles and combined potency analysis. Eur. J. Pharmacol. 78: 421-429, 1982.
62. WALKER, J. M., MOISES, H. C. COY, D. H., BALDRIGHI, G. AND AKIL, H.: Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science 218: 1136-1138, 1982a.
63. WALKER, J. M., MOISES, H. C. COY, D. H., YOUNG, E. A., WATSON, S. J. AND AKIL, H.: Dynorphin (1-17): lack of analgesia but evidence for nonopiate electro-physiological and motor effects. Life Sci. 31: 1821-1824, 1982b.
64. WEN, H. L. AND Ho, W. K. K.: Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur. J. Pharmacol. 82: 183-186, 1982.
65. WEN, H. L., HO, W. K. K. AND WEN, P. Y. C.: Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur. J. Pharmacol. 100: 155-162, 1984.
66. WEN, H. L., MEHAL, Z. D., ONG, B. H. AND HO, W. K. K.: Treatment of pain in cancer patients by intrathecal administration of dynorphin. Peptides 8: 191-193, 1987.
67. WEN, H. L., MEHAL, Z. D., ONG, B. H., HO, W. K. K. AND WEN, D. Y. K.: Intrathecal administration of beta-endorphin and dynorphin-(1-13) for the treatment of intractable pain. Life Sci. 37: 1213-1220, 1985.
68. WOO, S. K., TULUNAY, F. C., LOH, H. H. AND LEE, N. M.: Effect of dynorphin-(1-13) and related peptides on respiratory rate and morphine-induced respiratory rate depression. Eur. J. Pharmacol. 96: 117-122, 1983.
69. WÜTSTER, M., RUBINI, P. AND SCHULZ, R.: The preference of putative proenkepha-lins for different types of opiate receptors. Life Sci. 29: 1219-1227, 1981.
70. WÜSTER, M., SCHULZ, R. AND HERZ, A.: Highly specific opiate receptor for dynorphin-(1-13) in the mouse vas deferens. Eur. J. Pharmacol. 62: 235-236, 1980.
71. YOSHIMURA, K., HUIDOBRO-TORO, J. P., LEE, N. M., LOH, H. H. AND WAY, E. L.: Kappa opioid properties of dynorphin and its peptide fragments on the guinea pig ileum. J. Pharmacol. Exp. Ther. 222: 71-79, 1982.
72. 3H-dynorphin A in vivo and m vitro. International Narcotic Research Conference, Falmouth, MA, 1985.